ArticleAmerican journal of translational research2021
Therapeutic effects of alteplase intravenous thrombolysis on different types of acute cerebral infarction: a controlled randomized analysis.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo test the effects of alteplase (PA) intravenous thrombolysis on different types of acute cerebral infarction (ACI).
methodsOne hundred and ten patients with the ACI admitted from April 2018 to April 2019 were selected and randomly assigned to a research group and a reference group equally. The two groups received conventional treatment with a subcutaneous injection of low molecular weight heparin calcium of 5000 IU, and the research group received additional PA intravenous thrombolysis treatment. The therapeutic effects of the two groups were compared.
resultsThere were no significant differences in terms of general information and National Institutes of Health Stroke Scale (NIHSS) score at T0 (P>0.05) between the two groups; the research group garnered better results in the NIHSS scores at T1, T2, T3, and T4 than the reference group (P<0.001); a decrease was found in the Modified Rankin Scale (MRS) after treatment (P<0.001), with lower scores in the research group (P<0.001); the research group obtained a higher total effective rate than the reference group (P<0.05). Remarkably higher Barthel scores of the two groups after treatment were found (P<0.001), with higher scores collected from the research group (P<0.001); patients in the research group enjoyed a lower incidence of bleeding events than the reference group (P<0.05). The levels of Interleukin-1β (IL-1β), high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor alpha (TNF-α), superoxide dismutase (SOD), glutathione peroxidase (GSH-px), and malondialdehyde (MDA) were apparently optimized after treatment, with superior results observed in the research group (P<0.05).
conclusionPA intravenous thrombolysis effectively improves the neurological function of patients with different types of ACI and their quality of life, and reduces bleeding events, which is worthy of promotion.
Indexed as
Identifiers
34540027PMC8430132W3199648677What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.